Autres langues Pharvaris N.V.

Actions

PHVS

NL00150005Y4

Temps Différé Nasdaq Autres places de cotation 15:30:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
23,25 ^USD	-0,85 %		+9,21 %	-17,11 %

15/04	PHARVARIS N.V. : Morgan Stanley réitère son opinion positive sur le titre	ZM
10/04	Pharvaris réduit sa perte nette au quatrième trimestre et embauche un nouveau chef de la direction financière	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pharvaris Files Mixed Shelf	12/04
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference	04/04
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris N : Poster	15/03
Pharvaris N : EGM Meeting Minutes	12/03
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pharvaris N.V.

Actions

PHVS

NL00150005Y4

Autres langues

Filtres